dQ&A launched the beta of our next-gen AI Insights Platform—a breakthrough natural language solution providing instant, data-driven answers for the diabetes market.
dQ&A Presented Three Abstracts at EASD 2023 | dQ&A
New dQ&A data tracks GLP-1 & SGLT2 trends, patient/HCP insights, satisfaction, and market shifts to guide diabetes drug decisions.
We partnered with LMC to connect real-world patient experience insights with validated clinical data for patients across the diabetes spectrum.
Our survey of 190 U.S. endocrinologists finds GLP-1 and SGLT2 prescribing at 90%+ and rising, while many patients resist starting basal insulin.
A dQ&A-CeQur study in Clinical Diabetes finds 2 months on the CeQur Simplicity insulin patch boosts patient satisfaction, cuts burden, and lifts well-being.
This article reports results of a survey of patients and health care providers regarding their experiences of and challenges with the use of basal insulin.
dQ&A research reveals primary care challenges in adopting diabetes tech, highlighting needs for CGM training, simpler tools, and better industry support.
Our research finds Mounjaro patients report health benefits but face confusion and frustration during therapy initiation.
